Published in Mol Med Rep on April 13, 2016
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Serum microRNAs are promising novel biomarkers. PLoS One (2008) 8.69
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
MicroRNA-cancer connection: the beginning of a new tale. Cancer Res (2006) 7.38
Detection and characterization of placental microRNAs in maternal plasma. Clin Chem (2008) 6.40
Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods (2010) 6.25
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol (2010) 5.92
MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 5.34
miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem (2007) 5.02
MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A (2011) 4.11
Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One (2010) 3.50
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem (2008) 3.00
Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol (2012) 2.91
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev (2010) 2.51
Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem (2011) 2.42
Pathology of lung cancer. Clin Chest Med (2002) 2.35
Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol (2004) 1.89
Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res (2011) 1.86
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84
MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology (2010) 1.82
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 1.79
miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget (2011) 1.73
Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology (2011) 1.73
Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia (2007) 1.73
MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis (2012) 1.40
Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J Natl Cancer Inst (2015) 1.18
A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res (2011) 1.10
A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res (2014) 1.09
MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med Oncol (2011) 1.07
Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma. Oncol Lett (2012) 0.94
Circulating microRNAs as biomarkers: a new frontier in diagnostics. Liver Transpl (2012) 0.86
MiRNAs in cancer: non-coding RNAs as appealing biomarkers for malignancy. Cancer Biomark (2012) 0.77
MicroRNA-4649-3p inhibits cell proliferation by targeting protein tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells. Int J Mol Med (2015) 0.78
Cyclin-dependent kinase 5 regulates the proliferation, motility and invasiveness of lung cancer cells through its effects on cytoskeletal remodeling. Mol Med Rep (2015) 0.77
NF-κB signaling modulates radiation‑induced microglial activation. Oncol Rep (2014) 0.77
Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report. Oncol Lett (2015) 0.75
Peripheral T-cell lymphoma complicated by immunoglobulin A pemphigus: A case report and literature review. Oncol Lett (2014) 0.75
Effect of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against human Merkel cell carcinoma MKL-1 cells. Oncol Lett (2015) 0.75
PAK6 promotes cervical cancer progression through activation of the Wnt/β-catenin signaling pathway. Oncol Lett (2020) 0.75